Avondale Patent-Cliff Exposure & CMS Drug Spending Portfolio

Avondale (US): 3 reconciled FDA prescription therapies, $110.0M 2024 CMS Part D & Medicaid spend, and $900 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$110.0M
2024 Medicare Part D Spend$67.9M
2024 Medicaid Spend$42.1M
California HCAI SB 17 FilingsSpecialty launch notice ($900 intro WAC)